cardenolid
plantderiv
toxic
substanc
cytotox
underli
mechanist
signal
axe
extens
document
antivir
activ
cardenolid
associ
signal
pathway
report
previous
report
varieti
cardenolid
impart
antitransmiss
gastroenter
coronaviru
tgev
activ
swine
testicular
st
cell
target
cell
membran
sodiumpotassium
pump
na
k
atpas
herein
explor
potenti
signal
cascad
associ
antitgev
activ
st
cell
ouabain
repres
cardenolid
found
potent
diminish
tgev
titer
inhibit
tgevinduc
product
dose
depend
manner
inhibitori
concentr
nm
nm
respect
pharmacolog
inhibit
gene
silenc
demonstr
signal
induc
tgevinfect
st
cell
ouabain
impart
degre
antitgev
activ
via
augment
exist
axi
signal
manner
depend
upon
associ
na
k
atpas
final
inhibit
antagon
antivir
activ
ouabain
restor
tgev
viru
titer
yield
find
first
report
signal
axi
induc
ouabain
implic
suppress
tgev
activ
replic
greatli
illumin
underli
mechan
cardenolid
toxic
expect
result
one
antivir
applic
cardenolid
futur
navasmartin
tgev
spike
protein
bind
porcin
cell
http
doi
cardenolid
plantderiv
toxic
substanc
use
small
dose
treat
hypotens
arrhythmia
recent
discov
exert
anticanc
antivir
activ
target
bind
membran
receptor
sodiumpotassium
pump
na
k
atpas
agraw
et
al
diederich
et
al
direct
bind
cardenolid
na
k
atpas
locat
cell
membran
induc
endocytosi
reduc
amount
na
k
atpas
cellular
surfac
perturb
homeostasi
cell
solut
henc
elev
intracellular
calcium
level
diederich
et
al
newman
et
al
prassa
diamandi
explor
novel
antivir
associ
signal
axe
cardenolid
expect
illumin
underli
mechan
toxic
isoform
na
k
atpas
consist
three
subunit
one
alpha
one
beta
one
gamma
four
three
one
kind
respect
baker
bechmann
et
al
diederich
et
al
katz
et
al
alpha
subunit
na
k
atpas
wellknown
cellular
target
cardiac
glycosid
select
variou
isoform
na
k
atpas
vari
due
structur
divers
alpha
beta
subunit
habeck
et
al
katz
et
al
use
cardenolid
combat
human
cancer
reduc
viral
product
previous
explor
diederich
et
al
nagai
et
al
platz
et
al
su
et
al
tomita
kuwata
bind
cardenolid
na
k
atpas
inhibit
activ
solut
pump
also
result
recruit
na
k
atpas
associ
signalsom
cancer
cell
initi
associ
signal
pathway
henc
anticardiovascular
dysfunct
anticanc
biolog
activ
diederich
et
al
newman
et
al
prassa
diamandi
signal
involv
srcmediat
cytostat
effect
cell
death
pathway
includ
nonapoptot
cell
death
apoptosi
autophagi
mitophagi
nuclear
event
includ
transcript
activ
epigenet
effect
etc
diederich
et
al
howev
report
investig
antivir
mechan
cardenolid
burkard
et
al
yang
et
al
transmiss
gastroenter
coronaviru
tgev
infect
pig
caus
transmiss
gastroenter
high
mortal
weiss
receptor
aminopeptidas
n
aid
entri
tgev
cell
swine
testicular
st
cell
use
host
cell
line
tgev
mani
studi
sinc
st
cell
express
aminopeptidas
n
highli
suscept
tgev
delma
et
al
oh
et
al
weingartl
derbyshir
weiss
navasmartin
previous
report
varieti
cardenolid
includ
ouabain
exert
potent
antitgev
activ
yang
et
al
knock
express
na
k
atpas
decreas
tgev
infect
st
cell
yang
et
al
exact
associ
effect
pathway
remain
investig
herein
disclos
result
studi
underli
antitgev
mechan
ouabain
found
ouabain
enhanc
exist
na
k
atpasedepend
signal
axi
initi
activ
tgev
infect
st
cell
augment
na
k
atpasedepend
signal
axi
activ
ouabain
contribut
antitgev
activ
replic
cw
yang
et
al
toxicolog
appli
pharmacolog
discoveri
novel
signal
axi
initi
upon
bind
ouabain
na
k
atpas
greatli
illumin
underli
mechan
cardenolid
toxic
expect
result
one
antivir
applic
cardenolid
futur
st
cell
purchas
atcc
cultur
minimum
essenti
medium
mem
gibco
grand
island
ny
usa
supplement
fetal
bovin
serum
fb
biolog
industri
beit
haemek
israel
penicillinstreptomycin
biolog
industri
beit
haemek
israel
humidifi
incub
co
atmospher
taiwan
field
isol
virul
strain
tgev
propag
st
cell
cultur
mem
fb
ifa
studi
mechanist
signal
effector
regard
ouabain
pharmacolog
inhibitor
tgev
infect
st
cell
perform
describ
yang
et
al
yang
et
al
briefli
st
cell
plate
without
pretreat
test
compound
infect
tgev
moi
h
tgev
infect
st
cell
fix
subject
indirect
ifa
antibodi
nucleocapsid
n
protein
tgev
cell
treat
eight
differ
concentr
test
compound
result
cell
incub
fluorescein
isothiocyanateconjug
antimous
immunoglobulin
cappel
icn
pharmaceut
inc
fluoresc
intens
measur
determin
inhibitori
concentr
ic
inhibit
n
protein
express
result
assay
use
obtain
doserespons
curv
ic
determin
test
compound
pretreat
h
st
cell
infect
tgev
moi
ifa
analys
signal
effector
viral
copi
number
hpi
ii
moi
determin
viru
titer
product
hpi
indic
time
point
western
blot
perform
describ
yang
et
al
follow
antibodi
pakt
pakt
akt
gapdh
cell
signal
technolog
inc
usa
na
k
atpas
abcam
inc
cambridg
uk
antibodi
tgev
n
protein
describ
yang
et
al
ouabain
hplc
purchas
sigmaaldrich
st
loui
mo
usa
antibodi
rottlerin
rapamycin
triciribin
purchas
merck
millipor
calbiochem
billerica
selleckchem
houston
tx
usa
farnesyl
thiosalicyl
acid
fta
inhibitor
purchas
santa
cruz
biotechnolog
santa
cruz
ca
wortmannin
purchas
life
technolog
san
diego
ca
usa
experi
perform
describ
yang
et
al
mock
tgev
infect
moi
st
cell
process
result
cell
lysat
prepar
hpi
without
compound
treatment
subsequ
total
rna
extract
trizol
reagent
invitrogen
prior
rtqpcr
analys
primer
pair
use
rtqpcr
list
tabl
viral
copi
number
determin
describ
yang
et
al
known
amount
number
plasmid
yang
et
al
pro
yang
et
al
use
establish
standard
curv
determin
tgev
viral
copi
number
screen
cellular
signal
pharmacolog
inhibitor
identifi
abl
revers
antitgev
effect
ouabain
shown
residu
activ
treatment
pharmacolog
inhibitor
compar
dmso
vehicl
treatment
tgev
activ
use
ifa
describ
method
detect
n
protein
express
appli
measur
tgev
activ
compar
ouabain
treatment
result
shown
averag
sd
three
independ
experi
conduct
duplic
p
compar
ouabain
treatment
compar
ouabain
treatment
amount
porcin
cytokin
measur
describ
yang
et
al
briefli
supernat
tgev
infect
st
cell
moi
harvest
indic
period
amount
secret
determin
use
enzymelink
immunosorb
assay
kit
porcin
r
system
inc
appropri
dilut
perform
prior
determin
amount
harvest
supernat
contain
concentr
high
accur
assay
use
enzymelink
immunosorb
assay
kit
st
cell
harbor
shrna
clone
id
shrna
clone
id
shrna
clone
id
shrna
clone
id
shrna
clone
id
neg
controlshrna
shlacz
clone
id
shlacz
clone
id
academia
sinica
taiwan
respect
specif
gene
silenc
prepar
describ
previous
yang
et
al
valid
na
k
atpas
knockdown
express
select
cell
use
follow
experi
viru
titer
determin
end
point
dilut
assay
describ
yang
et
al
briefli
supernat
obtain
cultur
tgev
infect
st
cell
moi
hpi
indic
treatment
subject
viral
titer
determin
via
end
point
dilut
assay
tissu
cultur
infect
dose
determin
reedmuench
method
use
measur
infecti
tgev
viru
titer
approxim
tcid
pfu
plaqueform
unit
statist
signific
two
group
evalu
twotail
unpair
student
ttest
use
denot
statist
signific
p
p
respect
cardenolid
previous
found
potent
inhibit
tgev
activ
st
cell
without
signific
cytotox
concentr
cytotox
st
cell
yang
et
al
select
ouabain
fig
fig
inhibit
antagon
antitgev
activ
ouabain
inhibit
attenu
potenc
antitgev
activ
ouabain
ifa
assay
increas
ic
valu
shift
dosedepend
inhibit
curv
right
b
inhibit
rescu
tgev
n
protein
level
significantli
inhibit
ouabain
determin
western
analysi
c
quantif
statist
signific
analysi
b
st
cell
pretreat
indic
test
compound
min
treat
ouabain
h
prior
tgev
infect
moi
observ
fluoresc
intens
measur
ifa
western
analysi
indic
antibodi
b
hpi
st
cell
fix
subject
indirect
ifa
antibodi
n
protein
tgev
obtain
n
protein
express
ifa
western
analysi
use
indic
tgev
activ
p
p
compar
tgev
infect
control
compar
tgev
infect
ouabain
treatment
n
protein
pakt
normal
gapdh
result
shown
repres
result
b
averag
sd
three
independ
experi
c
titer
pfu
ml
yang
et
al
expect
tgev
infect
st
cell
moi
hpi
ouabain
diminish
viral
titer
viral
yield
even
low
dose
dosedepend
manner
inhibitori
concentr
ic
nm
ultim
ouabain
treatment
concentr
nm
result
reduct
viral
titer
order
magnitud
fig
similarli
ouabain
treatment
result
reduct
number
viral
rna
copi
order
magnitud
tgev
infect
st
cell
moi
hpi
fig
moreov
tgev
infect
moi
induc
sustain
product
h
period
st
cell
fig
induct
profoundli
diminish
ouabain
dose
depend
manner
ic
nm
fig
identifi
signal
pathway
involv
antitgev
activ
ouabain
comprehens
examin
ouabainrel
cellular
event
antitgev
activ
screen
varieti
pharmacolog
inhibitor
sever
signal
pathway
tabl
inhibitor
significantli
revers
antitgev
activ
ouabain
determin
ifa
tabl
fig
viral
n
antigen
express
antitgev
ic
valu
ouabain
ic
nm
increas
presenc
ic
nm
ic
nm
respect
inhibit
curv
exhibit
signific
rightshift
presenc
fig
fig
ouabain
activ
axi
signal
lead
inhibit
tgev
activ
ouabain
antitgev
activ
mediat
axi
signal
b
ouabain
antitgev
activ
mediat
axi
signal
c
ouabain
antitgev
activ
mediat
signal
st
cell
pretreat
indic
test
compound
min
treat
ouabain
h
prior
tgev
infect
moi
h
result
cell
harvest
western
analysi
indic
antibodi
ns
signific
p
p
compar
tgev
infect
control
compar
tgev
infect
ouabain
treatment
n
protein
pakt
normal
gapdh
normal
regular
result
shown
repres
result
averag
sd
three
independ
experi
tgev
infect
induc
akt
phosphoryl
ouabain
treatment
augment
akt
phosphoryl
inhibitor
elimin
tgev
induc
ouabain
enhanc
akt
phosphoryl
fig
ouabain
report
bind
na
k
atpas
result
recruit
na
k
atpas
associ
signalsom
turn
trigger
signal
pharmacolog
effect
ouabain
liu
et
al
nguyen
et
al
support
observ
treatment
inhibit
ouabain
associ
activ
demonstr
abolish
akt
phosphoryl
rescu
tgev
n
protein
express
level
indic
tgev
prolifer
fig
c
activ
mediat
ouabain
enhanc
activ
associ
na
k
atpas
contribut
antitgev
activ
pharmacolog
inhibit
strategi
use
examin
involv
akt
mtor
downstream
signal
cascad
antitgev
activ
ouabain
fig
two
dose
ouabain
nm
nm
close
ic
valu
nm
determin
ifa
fig
use
follow
studi
fig
akt
inhibitor
triciribin
abl
inhibit
akt
phosphoryl
fail
rescu
diminish
n
protein
express
ouabain
accomplish
inhibitor
fig
similarli
mtor
inhibitor
rapamycin
abl
diminish
phosphoryl
fail
revers
inhibit
n
protein
express
ouabain
fig
inhibitor
abl
revers
ouabaininhibit
tgev
n
protein
express
ouabain
treatment
increas
phosphoryl
fig
phosphoryl
significantli
affect
data
shown
treatment
inhibit
phosphoryl
downstream
effector
hao
et
al
et
al
sun
et
al
utepbergenov
et
al
fig
furthermor
na
k
atpas
deplet
st
cell
infect
tgev
tgev
n
protein
express
significantli
suppress
compar
control
shrna
harbor
st
cell
fig
yang
et
al
wherein
phosphorylationact
fig
effect
knockdown
express
na
k
atpas
tgev
activ
knockdown
na
k
atpas
express
activ
axi
pathway
suppress
tgev
activ
b
c
knockdown
b
express
c
revers
ouabaininhibit
tgev
activitytgev
n
protein
express
valid
knock
cell
seed
onto
wellplat
cellswel
cultur
h
prior
harvest
western
analysi
antibodi
indic
ns
signific
p
na
k
atpas
n
protein
normal
gapdh
normal
regular
result
shown
repres
result
averag
sd
three
independ
experi
gene
name
na
k
atpas
respect
significantli
increas
fig
moreov
deplet
st
cell
infect
tgev
tgev
n
protein
express
compar
amount
compar
control
shrna
harbor
st
cell
fig
c
howev
cell
treat
ouabain
n
protein
significantli
suppress
control
shrna
harbor
st
cell
deplet
abl
significantli
revers
ouabaininhibit
tgev
n
protein
express
fig
c
therefor
conclud
ouabain
target
na
k
atpas
led
enhanc
axi
signal
turn
impart
antitgev
activ
ouabain
potent
elimin
tgev
titer
dosedepend
manner
fig
inhibitor
inhibitor
block
signal
antagon
effect
fig
test
whether
effect
result
diminish
viru
titer
found
significantli
rescu
tgev
replicationtit
inhibit
ouabain
fig
thu
ouabain
reduc
tgev
viral
replicationtit
least
part
via
enhanc
activ
signal
cascad
cardenolid
elev
concentr
calcium
cytoplasm
caus
muscl
contract
thu
use
treat
cardiac
dysfunct
diederich
et
al
recent
use
anticanc
drug
investig
baker
bechmann
et
al
diederich
et
al
underli
mechan
process
howev
remain
unravel
previous
report
cardenolid
exert
potent
antivir
activ
tgev
infect
st
cell
yang
et
al
herein
disclos
result
investig
underli
mechan
activ
discoveri
enhanc
activ
axi
tgev
infect
st
cell
contribut
antitgev
activ
ouabain
herein
cell
separ
infect
moi
screen
compound
dissect
signal
pathway
use
western
analys
ifa
etc
accur
ascertain
antivir
potenc
first
screen
pharmacolog
inhibitor
search
counteract
antitgev
activ
ouabain
inhibitor
abl
significantli
counteract
antitgev
activ
ouabain
tabl
recent
na
k
atpas
subunit
mediat
src
signal
report
inhibit
anoth
coronaviru
murin
hepat
viru
hela
cell
transfect
plasmid
contain
humanderiv
murinederiv
na
k
atpas
subunit
burkard
et
al
also
report
cardenolid
exert
antimurin
hepat
viru
activ
murin
astrocytoma
dbt
cell
yang
et
al
howev
signific
counteract
found
among
three
src
inhibitor
util
herein
screen
tabl
effect
concentr
signal
data
shown
thu
role
src
signal
anticoronavirus
vari
depend
natur
na
k
atpas
isoform
exact
cell
type
burkard
et
al
yang
et
al
addit
although
src
associ
signal
cascad
report
respons
biolog
effect
cardenolid
cardiac
liu
et
al
zhang
et
al
cancer
cell
tian
et
al
respect
ouabain
also
activ
na
k
atpas
associ
signal
src
independ
wu
et
al
therefor
examin
downstream
effector
akt
mtor
found
inhibitor
abl
revers
antitgev
activ
ouabain
fig
na
k
atpas
knock
st
cell
signific
amount
n
protein
express
suppress
reflect
decreas
viru
infect
howev
knock
st
cell
cell
becam
resist
ouabain
treatment
control
shrna
harbor
st
cell
reflect
revers
viru
infect
fig
final
combin
treatment
either
ouabain
success
revers
activ
ouabain
increas
tgev
titer
fig
cardenolid
use
treat
hypotens
arrhythmia
blood
concentr
attain
patient
low
hauptman
et
al
futur
develop
cardenolid
treatment
coronaviru
infect
mind
vitro
observ
report
herein
inform
therapeut
dosag
requir
conclus
mechan
action
antitgev
activ
ouabain
elucid
found
mediat
na
k
atpasedepend
axi
novel
cardenolid
pharmacolog
signal
cascad
fundament
mechanist
insight
expect
contribut
futur
applic
antivir
cardenolid
fig
ouabain
elimin
tgev
titer
via
augment
na
k
atpas
depend
axi
combin
treatment
either
ouabain
significantli
rescu
tgev
replicationtit
inhibit
ouabain
st
cell
pretreat
indic
compound
h
infect
tgev
multipl
infect
moi
result
cultur
medium
harvest
hpi
subject
determin
viru
titer
endpoint
assay
describ
materi
method
p
p
result
shown
averag
sd
three
independ
experi
